• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Aptose Biosciences, Inc. - Common Shares (NQ: APTO )

0.2790 +0.1088 (+63.92%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Aptose Biosciences, Inc. - Common Shares

< Previous 1 2 3 4 5 6 Next >
Why FedEx Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket
December 20, 2024
Via Benzinga
Aptose Announces Positive Decision by Nasdaq Hearings Panel
December 19, 2024
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose Announces Publication of Preclinical Data in AACR Journal Demonstrating Tuspetinib’s Unique Mechanism of Action and Synthetic Lethality on AML Cells When Combined with Venetoclax
December 12, 2024
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose Clinical Data Featured in Poster Presentation at the 2024 ASH Annual Meeting Support Tuspetinib Triple Drug Therapy for Newly Diagnosed AML
December 09, 2024
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose Signs CRADA with NCI to Develop Tuspetinib for AML and MDS in Newly Launched MyeloMATCH Precision Medicine Trials
December 03, 2024
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose Biosciences Inc. Announces Closing of $8 Million Public Offering
November 25, 2024
From Aptose Biosciences, Inc.
Via GlobeNewswire
Why Uxin Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
November 25, 2024
Via Benzinga
S&P 500 Moves Higher; Intuit Shares Fall Following Q1 Results
November 22, 2024
Via Benzinga
Topics Stocks
Exposures US Equities
Crude Oil Gains Over 1%; Ross Stores Earnings Top Views
November 22, 2024
Via Benzinga
Exposures Fossil Fuels
Dow Jumps 300 Points; Gap Posts Upbeat Earnings
November 22, 2024
Via Benzinga
Topics Stocks
Exposures US Equities
Aptose Biosciences Inc. Announces Pricing of $8 Million Public Offering
November 22, 2024
From Aptose Biosciences, Inc.
Via GlobeNewswire
Why Elastic Shares Are Trading Higher By 29%; Here Are 20 Stocks Moving Premarket
November 22, 2024
Via Benzinga
Aptose Initiates TUSCANY Phase 1/2 Study for Newly Diagnosed AML Patients to Receive Tuspetinib-based Triplet Therapy
November 20, 2024
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose Reports Results for the Third Quarter 2024
November 08, 2024
Aptose and Hanmi Pharmaceutical Co-developing Triplet Therapy of Tuspetinib with Azacitidine and Venetoclax for Newly Diagnosed AML 
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose Announces Results from Special Meeting of Shareholders
September 05, 2024
From Aptose Biosciences, Inc.
Via GlobeNewswire
Why Zhibao Technology Shares Are Trading Higher By Around 19%; Here Are 20 Stocks Moving Premarket
September 03, 2024
Via Benzinga
Hello Group, Zscaler And 3 Stocks To Watch Heading Into Tuesday
September 03, 2024
Via Benzinga
Aptose Receives $10 Million Through a Facility Agreement with Hanmi; Negotiating Future Collaboration Agreement with Hanmi to Jointly Develop Tuspetinib
August 30, 2024
Proceeds to be used for development of lead compound tuspetinib in combination therapy as frontline treatment for newly diagnosed AML patients 
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose Announces Adjournment of its Special Meeting of Shareholders
August 15, 2024
From Aptose Biosciences, Inc.
Via GlobeNewswire
APTO Stock Earnings: Aptose Biosciences Beats EPS for Q2 2024
August 09, 2024
APTO stock results show that Aptose Biosciences beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
Aptose Reports Results for the Second Quarter 2024
August 08, 2024
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose Announces Receipt of Deficiency Notice from Nasdaq
July 19, 2024
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose Announces Results from Annual and Special Meeting of Shareholders
June 18, 2024
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose Presents Tuspetinib (TUS) Clinical and Preclinical Findings at European Hematology Association (EHA) 2024 Hybrid Congress
June 14, 2024
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose Announces Closing of $4.43 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
June 03, 2024
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose Announces $4.43 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
May 31, 2024
From Aptose Biosciences, Inc.
Via GlobeNewswire
APTO Stock Earnings: Aptose Biosciences Beats EPS for Q1 2024
May 14, 2024
APTO stock results show that Aptose Biosciences beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
Aptose Reports Results for the First Quarter 2024
May 14, 2024
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose to Report First Quarter 2024 Financial Results and Provide Clinical Strategy Update on Tuesday, May 14, 2024
May 06, 2024
From Aptose Biosciences, Inc.
Via GlobeNewswire
APTO Stock Earnings: Aptose Biosciences Beats EPS for Q4 2023
March 26, 2024
APTO stock results show that Aptose Biosciences beat analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 Next >
Site Logo
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap